The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia

Tumor cells promote the suppression of host anti-tumor type 1 T cell responses by various mechanisms, including the upregulation of surface inhibitory molecules such as programmed death ligand (PD-L)-1, and the production of immunosuppressive cytokines such as interleukin-10 (IL-10). There are over...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Laura Jimbu, Oana Mesaros, Alexandra Neaga, Ana Maria Nanut, Ciprian Tomuleasa, Delia Dima, Corina Bocsan, Mihnea Zdrenghea
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	PD-1 PD-L1 IL-10 acute myeloid leukemia cancer Medicine R Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/30fd7aa677ee4ac38f6d8cd9ed008ba7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:30fd7aa677ee4ac38f6d8cd9ed008ba7
record_format	dspace
spelling	oai:doaj.org-article:30fd7aa677ee4ac38f6d8cd9ed008ba72021-11-25T18:39:23ZThe Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia10.3390/ph141111051424-8247https://doaj.org/article/30fd7aa677ee4ac38f6d8cd9ed008ba72021-10-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1105https://doaj.org/toc/1424-8247Tumor cells promote the suppression of host anti-tumor type 1 T cell responses by various mechanisms, including the upregulation of surface inhibitory molecules such as programmed death ligand (PD-L)-1, and the production of immunosuppressive cytokines such as interleukin-10 (IL-10). There are over 2000 trials investigating PD-L1 and/or its receptor programmed-death 1 (PD-1) blockade in cancer, leading to the approval of PD-1 or PD-L1 inhibitors in several types of solid cancers and in hematological malignancies. The available data suggest that the molecule PD-L1 on antigen-presenting cells suppresses type 1 T cell immune responses such as cytotoxicity, and that the cytokine IL-10, in addition to downregulating immune responses, increases the expression of inhibitory molecule PD-L1. We hypothesize that the manipulation of both the co-inhibitory network (with anti-PD-L1 blocking antibodies) and suppressor network (with anti-IL-10 blocking antibodies) is an attractive immunotherapeutic intervention for acute myeloid leukemia (AML) patients ineligible for standard treatment with chemotherapy and hematopoietic stem cell transplantation, and with less severe adverse reactions. The proposed combination of these two immunotherapies represents a new approach that can be readily translated into the clinic to improve the therapeutic efficacy of AML disease treatment.Laura JimbuOana MesarosAlexandra NeagaAna Maria NanutCiprian TomuleasaDelia DimaCorina BocsanMihnea ZdrengheaMDPI AGarticlePD-1PD-L1IL-10acute myeloid leukemiacancerMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1105, p 1105 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PD-1 PD-L1 IL-10 acute myeloid leukemia cancer Medicine R Pharmacy and materia medica RS1-441
spellingShingle	PD-1 PD-L1 IL-10 acute myeloid leukemia cancer Medicine R Pharmacy and materia medica RS1-441 Laura Jimbu Oana Mesaros Alexandra Neaga Ana Maria Nanut Ciprian Tomuleasa Delia Dima Corina Bocsan Mihnea Zdrenghea The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
description	Tumor cells promote the suppression of host anti-tumor type 1 T cell responses by various mechanisms, including the upregulation of surface inhibitory molecules such as programmed death ligand (PD-L)-1, and the production of immunosuppressive cytokines such as interleukin-10 (IL-10). There are over 2000 trials investigating PD-L1 and/or its receptor programmed-death 1 (PD-1) blockade in cancer, leading to the approval of PD-1 or PD-L1 inhibitors in several types of solid cancers and in hematological malignancies. The available data suggest that the molecule PD-L1 on antigen-presenting cells suppresses type 1 T cell immune responses such as cytotoxicity, and that the cytokine IL-10, in addition to downregulating immune responses, increases the expression of inhibitory molecule PD-L1. We hypothesize that the manipulation of both the co-inhibitory network (with anti-PD-L1 blocking antibodies) and suppressor network (with anti-IL-10 blocking antibodies) is an attractive immunotherapeutic intervention for acute myeloid leukemia (AML) patients ineligible for standard treatment with chemotherapy and hematopoietic stem cell transplantation, and with less severe adverse reactions. The proposed combination of these two immunotherapies represents a new approach that can be readily translated into the clinic to improve the therapeutic efficacy of AML disease treatment.
format	article
author	Laura Jimbu Oana Mesaros Alexandra Neaga Ana Maria Nanut Ciprian Tomuleasa Delia Dima Corina Bocsan Mihnea Zdrenghea
author_facet	Laura Jimbu Oana Mesaros Alexandra Neaga Ana Maria Nanut Ciprian Tomuleasa Delia Dima Corina Bocsan Mihnea Zdrenghea
author_sort	Laura Jimbu
title	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
title_short	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
title_full	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
title_fullStr	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
title_full_unstemmed	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
title_sort	potential advantage of targeting both pd-l1/pd-l2/pd-1 and il-10–il-10r pathways in acute myeloid leukemia
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/30fd7aa677ee4ac38f6d8cd9ed008ba7
work_keys_str_mv	AT laurajimbu thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT oanamesaros thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT alexandraneaga thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT anamariananut thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT cipriantomuleasa thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT deliadima thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT corinabocsan thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT mihneazdrenghea thepotentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT laurajimbu potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT oanamesaros potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT alexandraneaga potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT anamariananut potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT cipriantomuleasa potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT deliadima potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT corinabocsan potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia AT mihneazdrenghea potentialadvantageoftargetingbothpdl1pdl2pd1andil10il10rpathwaysinacutemyeloidleukemia
_version_	1718410824735784960

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia

Ejemplares similares